In short
Clinical trials investigating Losartan Potassium are studying different patient groups and health problems, such as heart disease, brain tumors, kidney disease, and bone disorders. These studies look at outcomes like safety, symptom control, organ function, and disease progression. The article below explains what each trial is trying to learn.
Key points
- Clinical trials of Losartan Potassium are studying a wide range of conditions, including aortic stenosis, idiopathic IgA nephropathy, osteogenesis imperfecta, heart failure, brain tumors, and inflammatory heart involvement after COVID-19. The trial phases include Phase 2, Phase 3, Phase 4, and one low-intervention study. Some studies test Losartan Potassium alone, while others compare it with placebo or use it as part of a broader treatment plan. The main outcomes include changes in heart function, proteinuria, imaging measures, bone markers, and kidney stone or tissue changes. The target groups vary from adults with heart or kidney disease to patients with cancer, diabetes, or inherited bone disease.
Trial overview
These clinical trials study Losartan Potassium in different patient groups and disease settings. The trials are not all for the same illness, and they use different study designs, such as interventional studies, placebo comparisons, and open-label research.
Across the trial set, researchers are looking at whether Losartan Potassium can help with heart disease, kidney disease, bone disease, brain tumors, and inflammatory heart problems after COVID-19.
Heart and blood vessel studies
Several trials focus on heart failure and related heart conditions. One Phase 3 study in people with heart failure and recovered left ventricular ejection fraction compares stopping beta-blockers with continuing treatment, and Losartan appears as one of the treatment options in the study plan.
Another Phase 3 trial in type 2 diabetes studies high-dose treatment with RAS-antagonists and beta-blockers to reduce cardiac death or cardiac hospitalization, and Losartan is one of the drugs listed in that treatment group. A Phase 3 trial in aortic stenosis tests Losartan Potassium against placebo to see whether it slows the worsening of valve narrowing and valve calcification over 24 months.
A low-intervention trial in non-ischemic cardiomyopathy studies whether stopping neurohormonal therapy is no worse than keeping it in patients who had a strong response to cardiac resynchronization therapy. In this study, Losartan is one of many allowed drugs in the treatment background.
A Phase 2 heart failure study also includes Losartan among many comparison treatments while testing XXB750, with the main outcome being the change in NT-proBNP at Week 16.
Kidney, bone, and other conditions
Losartan Potassium is also being studied in idiopathic IgA nephropathy, which is a kidney disease where the immune system plays a role. This Phase 3 trial looks at proteinuria reduction, meaning less protein in the urine, over 4 to 10 months depending on the study arm.
A Phase 2 trial in osteogenesis imperfecta includes patients aged 16 years and older and measures change in CTX, a bone resorption marker, by Week 24. This study aims to find an effective dose of Losartan for that patient group.
A Phase 4 study called the GranStone Trial tests whether Losartan or empagliflozin can lower the risk of kidney stones and disease progression in paraffin oil induced granulomatous disease. The main outcome is image-verified new or increased nephrolithiasis or nephrocalcinosis between 1 and 24 months.
What outcomes are measured
The trials use different primary outcomes, which are the main results each study is built to measure. In heart studies, outcomes include recurrence of left ventricular dysfunction, heart failure relapse, changes in ejection fraction, changes in left ventricular volume, NT-proBNP levels, hospitalization, and urgent treatment visits.
In the aortic stenosis trial, researchers measure peak aortic velocity by echocardiography and valve calcification by non-contrast computed tomography after 24 months. In the brain tumor study, the main outcomes are radiographic biomarkers such as relative cerebral blood flow and tissue stiffness measured in the tumor area.
In kidney and bone studies, the outcomes include proteinuria, CTX, and imaging-confirmed kidney stone or calcium changes.
Who the trials include
The target populations are different from one study to another. Some trials include adults with heart failure or recovered ejection fraction, while others focus on people with type 2 diabetes, non-ischemic cardiomyopathy, aortic stenosis, IgA nephropathy, or paraffin oil induced granulomatous disease.
Some studies also include patients with newly diagnosed or recurrent glioblastoma, or brain metastases from non-small-cell lung cancer. One trial specifically includes older adolescents and adults aged 16 years and above with osteogenesis imperfecta.
Trial phases and designs
The trial set includes Phase 2, Phase 3, Phase 4, and low-intervention research. Phase 2 studies usually explore early signs of benefit and help find the right dose, while Phase 3 studies compare treatments in larger groups and look more closely at effectiveness.
One trial is completed, several are authorised, and the study designs include interventional treatment, placebo control, and open-label testing, meaning both the researchers and participants know what treatment is given in that study.